Northern lights could be visible in these states: See forecast map
About 15 states could catch a glimpse of the aurora borealis on Aug. 9, according to the latest forecast from the National Oceanic and Atmospheric Administration's Space Weather Prediction Center.
An earlier forecast for Friday, Aug. 8, showed a possibility of seeing the aurora in about 18 states was downgraded to a lesser event shorter before 8 a.m. ET.
A coronal mass ejection, or large expulsions of plasma and magnetic field from the sun, lifted off the star on Aug. 5, raising expectations to cause geomagnetic activity, according to NOAA.
For Aug. 9, NOAA said it predicts a geomagnetic K-index of 5. The K-index measures geomagnetic activity and indicates how far away from the poles the northern lights could be visible, according to the agency. A Kp score between 3-5 indicates brighter and increased activity, per NOAA.
On another geomagnetic storm scale, NOAA ranks the event a G1, which is considered a minor event.
The northern lights, a natural phenomenon formally known as the aurora borealis, can project colorful lights in the night sky because of an interaction between the sun's plasma and Earth's magnetic field, according to the National Weather Service.
When could the northern lights be visible?
The best view of the northern lights is usually within an hour or two of midnight, according to NOAA.
The aurora is not visible during daylight hours, and is usually seen just after sunset or just before sunrise, according to the agency.
More news: What is Instagram map? How to turn location feature on and off
Where could the northern lights be visible? See map
Parts of about 15 states are within NOAA's forecasted "view line" for the northern lights on Aug. 9. The view line indicates the southernmost point where the aurora could be seen on the northern horizon.
The following states could catch a glimpse of the aurora, according to NOAA's forecasted view line:
Alaska
Idaho
Iowa
Maine
Michigan
Minnesota
Montana
New Hampshire
New York
North Dakota
South Dakota
Vermont
Washington
Wisconsin
Wyoming
Melina Khan is a national trending reporter for USA TODAY. She can be reached at melina.khan@usatoday.com.
This article originally appeared on USA TODAY: Will northern lights be visible this weekend? See aurora forecast map
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
a few seconds ago
- Forbes
Northern Lights Tuesday: These States May See Aurora And ‘Shooting Stars'
The Northern Lights may be visible in the U.S. on Tuesday and Wednesday just as the Perseid meteor shower peaks, according to a forecast by the National Oceanic and Atmospheric Administration's Space Weather Prediction Center. Despite the weekend's bright full moon rising later at night to entirely true dark skies, sky-watchers in around 10 U.S. states may have a chance to see the aurora borealis on the northern horizon as 'shooting stars' fall. The cause is a spate of solar flares on the sun after weeks of inactivity. The agency's three-day forecast indicates an uptick in geomagnetic activity overnight on Tuesday, Aug. 12 through Wednesday, Aug. 13. According to a NOAA forecast, the Kp index — which provides a rough guide to the intensity of aurora displays — may reach 4 during a G1 geomagnetic storm. 'The geomagnetic field is expected to reached active levels, with a chance for G1 (Minor) geomagnetic storms, over 12-13 Aug due to persistent influence from a positive polarity CH HSS,' reads a NOAA forecast. A positive polarity CH HSS is a stream of fast-moving solar wind from a coronal hole on the sun, which can cause geomagnetic storms and auroral displays. Where The Northern Lights May Be Visible NOAA's latest aurora viewlines indicate that aurora displays are a possibility in northern U.S. states and Canada, with 10 U.S. states having a chance after dark on Wednesday, June 25. Parts of U.S. states that could potentially see aurora — possibly only on camera — according to NOAA, include Alaska, Washington, northern Idaho, Montana, North Dakota, South Dakota, Minnesota, Wisconsin, Michigan and Maine.. Check NOAA's 30-minute forecast or use the Glendale App for up-to-the-minute forecasts. Why The Northern Lights Are Being Seen In The U.S. The possibility of displays of the aurora borealis at more southerly latitudes than is typical is down to an increase in solar activity, which is currently at a 23-year high due to the current solar maximum period. The sun is now thought to be on the wane, having peaked in late 2024, but the best aurora displays often occur in the few years after solar maximum. If the current solar cycle does have a long tail, good aurora sightings in the U.S. could result for a few years. When The Northern Lights Are Most Common March-April and September-October are the most geomagnetically active month of the year, with geomagnetic disturbances twice as likely in spring (and also in fall) as in winter and summer. They tend to be strongest in the week or two after the equinoxes (September 22, 2025 and March 20, 2026). Earth's axis tilts by 23.5 degrees, which is why we have seasons. It also puts Earth perpendicular to the sun at equinox. Since the solar wind's magnetic field is facing southward relative to the Earth, during equinox the geometry more easily allows charged particles from the sun to be accelerated down the field lines of the Earth's magnetic field. Wishing you clear skies and wide eyes.
Forbes
28 minutes ago
- Forbes
The Perseid Meteor Shower Peaks Tonight — How To See It At Its Best
The annual Perseid meteor shower will peak overnight on Monday, Aug. 12, through Tuesday, Aug. 13, with an uptick in 'shooting stars' expected despite the presence of a waning full moon. The result of a comet twice the size of the object thought to have killed the dinosaurs and one of the annual highlights of the stargazing calendar, it usually produces up to 75 'shooting stars' per hour, but rates will be down this year. A view of the 2023 Perseid meteor shower from the southernmost part of Sequoia National Forest, near Piute Peak. Debris from comet Swift-Tuttle creates the Perseids. NASA/Preston Dyches The annual Perseid meteor shower peaks on Monday, Aug. 12, through Tuesday, Aug. 13, but is unlikely to deliver the 75 'shooting stars' per hour that would normally be visible because of an 84%-lit waning gibbous moon. According to EarthSky, the peak of the Perseids is predicted for 20:00 UTC (4:00 p.m. EDT) on Aug. 12, which makes the very early mornings of Aug. 11, 12 and 13 likely to be when there are the most meteors. With bright moonlight all night on those dates, it's also worth looking after these dates, particularly on Aug. 15, when the moon will have decreased in brightness and will rise around midnight. Although 'shooting stars' can be seen anywhere in the night sky, the radiant point of Perseids is the constellation Perseus, which rises in the northeast as it gets dark during August in the Northern Hemisphere. The best chance may be just after sunset and before moonrise, when the sky is still dark, on Aug. 12. It's a narrow window. 'Some Perseids will be visible shortly before/during moonrise on the evening of Aug. 12, when the sky should still be dark,' said Dr. Qicheng Zhang, astronomer at Lowell Observatory in Flagstaff, Arizona, in an email. 'The overall rate of meteors will be lower at this time than in the early morning hours, but the rate of visible meteors might be comparable or even a bit higher than due to much fainter meteors being visible without the moon.' How To Watch A Meteor Shower In Strong Moonlight The strong moonlight will make the Perseids less impressive this year, but there are ways to maximize your chances. 'Watching from the shadow of, say, a house, tree, or mountain could be done to block direct moonlight when the moon is up and make viewing a bit more pleasant,' said Zhang. It's all because of 109P/Swift-Tuttle, a huge comet that takes 133 years to orbit the sun. Last in the solar system in 1992, its nucleus is 16 miles (26 kilometers) across, which is over twice the size of the comet or asteroid that is thought to have killed the dinosaurs, according to NASA. Further Reading Forbes Meet 'Ammonite' — A New World Just Found In The Solar System By Jamie Carter Forbes 20 Best Dark Sky Campsites In The U.S. For Stargazing, From Hipcamp By Jamie Carter Forbes See The Perseid Meteor Shower Now Before It Peaks, Experts Say By Jamie Carter
Medscape
29 minutes ago
- Medscape
Evidence-Based Guidelines Issued for LAAO Devices
Created to address the 'uncertainty and practice variation' that surrounds transcatheter left atrial appendage occlusion (LAAO), the Society for Cardiovascular Angiography and Interventions and the Heart Rhythm Society have published jointly the first set of guidelines for the use of the procedure. 'There is tremendous diversity in left atrial appendage occlusion practice regarding appropriate patients, periprocedural imaging, adjunctive medical therapy, and management of device leak and device-related thrombus,' said Andrew M. Goldsweig, MD, MS, director of cardiovascular clinical research at the University of Massachusetts-Baystate, in Springfield, Massachusetts, who led the group that wrote the recommendations. Nonvalvular atrial fibrillation (AF) is a major risk factor for stroke, and it is a condition that affects at least 12 million individuals in the US, according to data cited in the new guidelines. Oral anticoagulation is a first-line strategy for reducing stroke risk in patients with the arrhythmia, but the benefit is potentially compromised in people at high risk for bleeding. More Than 100K Implants Per Year and Growing Clots associated with nonvalvular AF commonly form in the left atrial appendage. The FDA has approved two LAAO systems for the prevention of stroke: the Amplatzer Amulet (Abbott) and the Watchman (Boston Scientific). Earlier this month, the FDA announced that Boston Scientific is recalling Watchman systems that were performed without the use of positive pressure-controlled ventilation. The agency said at least 120 people have been seriously injured, and 17 have died, after undergoing the procedure. For both systems, the current indication remains limited to people with contraindications to oral anticoagulation; however, the consensus expressed in the new guidelines is that this restriction is 'outdated' in the wake of evidence that has become available since the publication of pivotal trials that preceded approval of both available devices. How often devices are being implanted outside current FDA labeling is unclear, but LAAO has become 'one of the most frequent procedures' in cardiology, with an estimated 100,000 performed in 2024, according to data cited by Goldsweig. Eight evidence-based recommendations, covering patient selection, how imaging should be employed to assess and follow patients, and whether adjunctive oral anticoagulation should be considered in those with peridevice leak or device-related thrombus, were outlined in the new guidelines, which were simultaneously published in the Journal of the Society for Cardiovascular Angiography & Interventions and Heart Rhythm . Two address patient selection. The first reiterates the current indication, which is that LAAO should be considered in patients with nonvalvular AF with a contraindication to oral anticoagulation. The second identifies LAAO and oral anticoagulation as treatment options for patients with nonvalvular AF who do not necessarily have a contraindication to oral anticoagulation. Specifically, the guideline includes LAAO as an option for those 'with strong preferences to avoid long-term oral anticoagulation.' Based on current evidence, 'the main point of this recommendation is that LAAO is every bit as good as OAC [oral anticoagulant] — maybe even better — in terms of preventing atrial fibrillation-associated stroke,' Goldsweig said. Superiority for LAAO cannot be claimed because the large, randomized trials conducted to date have all employed a noninferiority design, Goldsweig acknowledged. Although earlier noninferiority trials, such as PREVAIL, compared LAAO to warfarin, most of the patients in the comparator group in the latest of these trials received a non-vitamin K oral anticoagulant. This trial, called OPTION, published earlier this year, compared arms for noninferiority on the primary composite endpoint of death from any cause, stroke, or systemic embolism at 36 months. Over the study period, the endpoint was reached by 8.5% in the LAAO group and 18.5% in the anticoagulation group, which easily met statistical significance for noninferiority. Superiority ( P < .001) for LAAO was also shown, but this result was hypothesis-generating given that the trial was not designed to study superiority. Trials May Expand Indications for LAAO Trials comparing LAAO to anticoagulant therapy as a first-line stroke prevention strategy among those who are candidates for either are underway. The CHAMPION-AF trial with the Watchman device and the CATALYST trial with the Amplatzer Amulet device in patients are in progress. Results are expected in 2026. Three other sets of recommendations involve periprocedural imaging, which is not being employed consistently across centers performing LAAO, according to Goldsweig. In one recommendation, pre-procedure transesophageal echocardiography or CT is identified as preferable to no such imaging. In the second and third, transesophageal echocardiography or CT are recommended, respectively, during and after the procedure. The remaining recommendations involve the use of oral anticoagulation following LAAO procedures with attention to peridevice leak and device-related thrombus, but data for these recommendations are generally limited, so they are accompanied by discussions of knowledge gaps. The authors of the guidelines caution that the relative role of oral anticoagulation and LAAO in nonvalvular AF is an evolving area. Many of the recommendations were labelled as 'conditional' based on evidence that generated 'low certainty.' Differences in relative acute and long-term costs, which were not addressed in the new guidelines, are another factor that might affect a stroke prevention strategy for individual patients. The Centers for Medicare and Medicaid Services announced a 27% reduction in the proposed 2026 Medicare fee schedule for the procedure. The American College of Cardiology, which attributed the proposed change to ' a proposed efficiency adjustment reduction,' is among several cardiology groups protesting the potential change. Some interventionalists have posted on social media that they can perform the procedure in under 10 minutes and about the safety of safe-day discharge of patients — practices that suggest clinicians are becoming more efficient with LAAO. But whether those statements influenced cardiometabolic syndrome is unclear. The expansion of LAAO past current indications is not uniformly embraced. John M. Mandrola, MD, a clinical electrophysiologist in Louisville, Kentucky, and host of the This Week in Cardiology podcast on has been a long-time critic of LAAO. The popularity of 'this well-compensated procedure has gotten ahead of the evidence,' he said. 'For evidence-minded physicians who are concerned about the rapid rise in LAAO procedures in patients without absolute contraindications to oral anticoagulants,' the conclusion that LAAO is as good as oral anticoagulation 'is very premature,' Mandrola said. Not least of his concerns, he noted that LAAO 'failed to show noninferiority to warfarin — a weaker comparator to the now commonly used direct-acting oral anticoagulants.' Mandrola said most patients now undergoing LAAO would not have been eligible for the pivotal Watchman vs warfarin trials. He has repeatedly called for a more conservative approach until proper trials provide evidence of equivalence. Mandrola said older patients with multiple competing causes of stroke — a common type of patient receiving LAAO — likely derive little to no net benefit from the focal strategy of appendage closure. The principal investigator of the recently published OPTION trial, Oussama Wazni, MD, MBA, section head of cardiac electrophysiology and pacing at the Cleveland Clinic in Cleveland, emphasized the need to consider risks and benefits. 'I think it is reasonable to consider LAAO as an alternative to oral anticoagulation' on the basis of patient preference, he said, but only 'after a careful and thorough shared decision discussion with patients regarding the potential acute complications and the potential for leaks and device-related thrombus.' Goldsweig, Mandrola, and Wazni reported having no relevant financial conflicts of interest.
